Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 11/20 | 0.36 |
| ▸ | MMP3 | P08254 | 11/20 | 0.36 |
| ▸ | MMP2 | P08253 | 8/20 | 0.36 |
| ▸ | MMP9 | P14780 | 5/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MMP7 | P09237 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16139218 | 0.80 | MAPT (0.42) | LMNAPIK3CDMAPT | |
| SCHEMBL14667924 | 0.79 | MMP1 (0.37) | MMP1MMP3MMP2MMP9MMP8 | |
| SCHEMBL22001875 | 0.74 | — | — | |
| SCHEMBL19010447 | 0.74 | TSHR (0.40) | MMP1MMP3MMP2MMP9MMP8 | |
| SCHEMBL14261374 | 0.74 | MAOA (0.35) | MMP1 | |
| SCHEMBL13588560 | 0.74 | HPGD (0.43) | LMNA | |
| SCHEMBL23874553 | 0.73 | LMNA (0.37) | MMP1MMP3MMP2MMP9MMP8 | |
| SCHEMBL13588557 | 0.73 | SLC22A6 (0.39) | LMNAMAPT | |
| SCHEMBL20440341 | 0.73 | LMNA (0.37) | MMP1MMP3MMP2MMP9MMP8 | |
| SCHEMBL17524636 | 0.73 | LMNA (0.37) | MMP1MMP3MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | MMP1 2042/4885MMP3 3393/4885MMP2 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.